Filing Flows › RxSight (RXST) › Q1 2025
RxSight (RXST) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 7, 2025
RxSight (RXST) reported revenue of $37.9M for the first quarter 2025 (Q1 2025), +28% from a year earlier and -6% from the quarter before. Operating margin was -28.2%, net loss $8.2M (21.6% of revenue).
RxSight, Q1 2025: revenue $37.9M (+28% year over year), operating margin -28.2%, net loss $8.2M, operating cash flow −$8.8M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $37.9M | -6% | +28% |
| Operating profit | −$10.7M | — | — |
| Net earnings | −$8.2M | — | — |
| Operating cash flow | −$8.8M | — | — |
What changed
Revenue was $37.9M in Q1 2025, up 28% year over year and down 6% from the previous quarter. Rxlal was the largest line at 72% of revenue. Rxlal added $7.3M year over year (up 37%), 87% of the total change.
Gross margin was 74.8%, up 4.7 points from a year earlier. Operating costs exceeded revenue by $10.7M, an operating margin of -28.2%. Operating expenses grew 24% against revenue growth of 28%. The fastest-growing cost line was Research & development (+29%). The quarter ended with a net loss of $8.2M, wider than the previous quarter's $5.9M loss. Non-operating items added $2.5M, -31% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$8.8M. Non-cash charges added back $776K of depreciation and amortization and $7.1M of share-based compensation. Working capital and other items used $8.6M. Capital expenditures of $575K exceeded it, leaving free cash flow of −$9.4M.
Questions
What was RxSight's revenue in the first quarter 2025?
RxSight (RXST) reported revenue of $37.9M for the first quarter 2025 (Q1 2025), +28% from a year earlier and -6% from the quarter before.
Was RxSight profitable in the first quarter 2025?
Operating loss was $10.7M (-28.2% of revenue) and net loss $8.2M.
Source: RxSight 10-Q on SEC EDGAR.